Protalix Q3 2026: Net Income $4.0M, YTD Revenue $75.6M, 2026 Guidance Reaffirmed
PLX sits 64% above its 52-week low of $1.65.
Summary
Protalix reported Q3 2026 net income of $4.0 million and $75.6 million of year-to-date revenue, reaffirming 2026 guidance of $78.0 million to $83.0 million with $48.5 million in cash and no debt or warrants.
Key Events · Earnings and Guidance · PLX
-
Q3 Profit and YTD Revenue Jump
Q3 2026 net income was $4.0 million, or $0.05 per share, versus $2.4 million a year earlier. Nine-month revenue reached $75.6 million, up $32.0 million from $43.6 million, including a $25.0 million Chiesi milestone.
-
2026 Guidance Reaffirmed
Management expects to meet or exceed 2026 total revenue of approximately $78.0 million to $83.0 million, including Elfabrio sales of $33.0 million to $35.0 million and Elelyso sales of $20.0 million to $23.0 million.
-
Balance Sheet: $48.5M Cash, No Debt
Cash, cash equivalents and short-term bank deposits were $48.5 million at September 30, 2026, and the company states it has no outstanding debt or warrants.
-
PRX-115 Data Not Until H2 2027
The Phase 2 RELEASE study in uncontrolled gout continues enrolling; top-line results are anticipated in the second half of 2027, leaving near-term performance dependent on product sales.
Analysis · PLX · Life Sciences
Protalix swung to a nine-month profit of $26.1 million from a $1.1 million loss a year earlier, driven by $75.6 million of year-to-date revenue that includes a $25.0 million Chiesi milestone. Management reaffirmed 2026 revenue guidance of roughly $78.0 million to $83.0 million and said it expects to meet or exceed that range, while holding $48.5 million in cash and deposits and carrying no debt or warrants. The remaining value driver is PRX-115 in uncontrolled gout, where Phase 2 RELEASE enrollment continues and top-line data are not expected until the second half of 2027 — so near-term results rest on Elfabrio and Elelyso product sales.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLX was trading at $2.71 on NYSE in the Life Sciences sector, with a market capitalization of approximately $207.1M. The 52-week trading range was $1.65 to $3.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.